Description
Invasive lobular carcinoma (ILC), also known as lobular breast cancer, is the second most common histological subtype of breast cancer. ILC has a unique biology and a distinct clinical pattern of behavior and is a challenging disease entity in terms of diagnostics, staging, and therapeutic options. There is a critical need to advance understanding of this disease and improve treatment and follow-up care options for patients living with ILC.
The AACR-Lobular Breast Cancer Alliance Invasive Lobular Carcinoma Research Fellowship is a joint effort to support and encourage innovative research projects with direct applicability and relevance to ILC and to help establish a successful career path in the field.
This fellowship provides a two-year grant of $130,000 to support the salary and benefits of postdoctoral or clinical research fellows working on mentored ILC research projects. A portion of these funds may be designated for non-personnel expenses such as research/laboratory supplies, equipment, publication charges for manuscripts that pertain directly to the funded project, and other research expenses.
Research Project Criteria
Research projects may be basic, translational, clinical, or population science-based, and must have direct applicability and relevance to invasive lobular carcinoma (ILC).
Citizenship Requirements
There are no citizenship or geographic requirements. However, by submitting an application for this grant, an applicant applying from an institution located in a country in which they are not a citizen or a permanent resident assures that the visa status will provide sufficient time to complete the project and grant term at the institution from which they applied.
LBCA itself does not publish a unified “success predictor” scoring rubric the way federal agencies do. However, based on its partnered grant programs and solicitations, the following are key factors that influence competitiveness and funding success:
✔ Alignment With ILC Focus
Proposals must be directly relevant to invasive lobular carcinoma or metastatic ILC — including research on biology, diagnostics, treatment, or prevention.
✔ Research Merit & Innovation
Grants like the AACR-LBCA Innovation & Discovery award aim to stimulate creative, novel approaches that might not be funded through conventional mechanisms.
✔ Career Stage Goals
Career development awards focus on early-career investigators with promising research plans in ILC, so the investigator’s potential and track record matter.
✔ Peer Review or Scientific Evaluation
Collaborative grants (e.g., with AACR/BCRF or Conquer Cancer/ASCO) are administered through established scientific review panels using criteria such as innovation, feasibility, and impact on lobular breast cancer outcomes — even if detailed scoring rubrics aren’t publicly posted.
✔ Proposal Clarity & Relevance
Strong, well-described research plans that clearly address unmet needs in ILC detection, biology, treatment, or metastasis tend to be more competitive.
The Lobular Breast Cancer Alliance (LBCA) actively collaborates with major cancer research funders like AACR, BCRF, ASCO/Conquer Cancer, and Susan G. Komen to fund ILC-focused research grants spanning innovation awards, career development support, and metastatic cancer research.
LBCA’s grant opportunities are designed to support novel ideas and early-career investigators and address significant gaps in invasive lobular carcinoma science.
There is no single formal success predictor model published by LBCA, but competitiveness is shaped by:
Direct relevance to ILC research
Scientific innovation and clarity of proposal
Investigator potential and career focus
Alignment with partnered funder priorities.
Applicants must have a doctoral degree (PhD, MD, MD/PhD, or equivalent) in a related field and not currently be a candidate for a further doctoral degree.
At the start of the grant term on July 1, 2026, applicants must:
Sponsor Institute/Organizations: Lobular Breast Cancer Alliance
Sponsor Type: Corporate/Non-Profit
Address: 615 Chestnut St., 17th Floor Philadelphia, PA 19106-4404
Affiliation Disclaimer: Trialect operates independently and is not affiliated with, endorsed by, or supported by any sponsors or organizations posting on the GrantsBoard platform. As an independent aggregator of publicly available funding opportunities, Trialect provides equal access to information for all users without endorsing any specific funding source, content, organization, or sponsor. Trialect assumes no responsibility for the content posted by sponsors or third parties.
Subscription Disclaimer: Upon logging into Trialect, you may choose to SUBSCRIBE to GrantsBoard for timely notifications of funding opportunities and to access exclusive benefits, such as priority alerts, reminders, personalized recommendations, and additional application support. However, users are advised to contact sponsors directly for any questions and are not required to subscribe to engage with funding opportunities.
Content Ownership and Copyright Disclaimer: Trialect respects the intellectual property rights of all organizations and individuals. All content posted on GrantsBoard is provided solely for informational purposes and remains the property of the original owners. Trialect does not claim ownership of, nor does it have any proprietary interest in, content provided by third-party sponsors. Users are encouraged to verify content and ownership directly with the posting sponsor.
Fair Use Disclaimer: The information and content available on GrantsBoard are compiled from publicly accessible sources in alignment with fair use principles under U.S. copyright law. Trialect serves as an aggregator of this content, offering it to users in good faith and with the understanding that it is available for public dissemination. Any organization or individual who believes their intellectual property rights have been violated is encouraged to contact us for prompt resolution.
Third-Party Posting Responsibility Disclaimer: Trialect is a neutral platform that allows third-party sponsors to post funding opportunities for informational purposes only. Sponsors are solely responsible for ensuring that their postings comply with copyright, trademark, and other intellectual property laws. Trialect assumes no liability for any copyright or intellectual property infringements in third-party content and will take appropriate action to address any substantiated claims.
Accuracy and Verification Disclaimer: Trialect makes no warranties regarding the accuracy, completeness, or reliability of the information provided by sponsors. Users are advised to verify the details of any funding opportunity directly with the sponsor before taking action. Trialect cannot be held liable for any discrepancies, omissions, or inaccuracies in third-party postings.
Notice and Takedown Policy: Trialect is committed to upholding copyright law and protecting the rights of intellectual property owners. If you believe that content on GrantsBoard infringes your copyright or intellectual property rights, please contact us with detailed information about the claim. Upon receipt of a valid notice, Trialect will promptly investigate and, where appropriate, remove or disable access to the infringing content.
Apr 09, 2026
Apr 09, 2026
$130,000
Affiliation: Lobular Breast Cancer Alliance
Address: 615 Chestnut St., 17th Floor Philadelphia, PA 19106-4404
Website URL: https://www.aacr.org/grants/aacr-lbca-invasive-lobular-carcinoma-research-fellowship/
Disclaimer:It is mandatory that all applicants carry workplace liability insurance, e.g., https://www.protrip-world-liability.com (Erasmus students use this package and typically costs around 5 € per month - please check) in addition to health insurance when you join any of the onsite Trialect partnered fellowships.